Crinetics Pharmaceuticals CRNX Operating lease right-of-use asset amortization
Operating lease right-of-use asset amortization at other companies
Other financials
Where this comes from
Reported directly by Crinetics Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense.
The official record: Crinetics Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Crinetics Pharmaceuticals's operating lease right-of-use asset amortization.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Crinetics Pharmaceuticals's operating lease right-of-use asset amortization?
- Crinetics Pharmaceuticals (CRNX) reported operating lease right-of-use asset amortization of $703K in Q1 2026.
- How has Crinetics Pharmaceuticals's operating lease right-of-use asset amortization changed year-over-year?
- Crinetics Pharmaceuticals's operating lease right-of-use asset amortization decreased by 13.5% year-over-year, from $813K to $703K.